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ABSTRACT
PROPENSITY SCORE MATCHING FOR SURGICAL OUTCOMES WITH
OBSERVATIONAL DATA
Robert M. Cannon, 3/26/2012
Because of limitations in randomized controlled trials, medical researchers are
often forced to rely upon studies of observational data. Confounding is a major difficulty
encountered in such studies that can create considerable bias in estimates of treatment
effects. Propensity score analysis was developed by Rosenbaum & Rubin in 1983 to
overcome these difficulties. In essence, a propensity score allows balance to be
achieved on confounding covariates in treatment and control groups, thus creating a
'quasi-randomized' trial from observational data. In this study, I illustrate the use of
propensity matching to demonstrate that African American race is a significant risk factor
for receiving a lower quality donor kidney using a national database on transplantation. I
then use propensity matching to demonstrate the benefits of laparoscopic resection for
hepatic colorectal metastases. In doing so, the great value of propensity matching in
reducing bias in observational studies is demonstrated.
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CHAPTER I
INTRODUCTION TO PROPENSITY SCORE METHODS
The goal of much of medical research is to evaluate the effect of a
particular intervention or exposure (which, hereafter I will refer to as a treatment) on a
given outcome of interest. For example one may wish to determine whether a new
chemotherapy regimen has a superior response rate compared to the current standard.
In the hierarchy of medical evidence, the randomized controlled trial (RCT) is considered
by many to be the gold standard for the assessment of such questions.
There are a number of important reasons for the value given to the RCT in
studies of causal inference. By the nature of randomization, the potential of bias in the
allocation of patients to either the treatment or control group is eliminated. As a corollary
to this property, a properly executed randomization scheme tends to produce treatment
and control groups that are balanced (that is, they have similar distributions) on relevant
covariates, both those that are measured and those that are unmeasured 1 . As I will
demonstrate, these characteristics allow for unbiased estimation of the effect of the
particular treatment under study.
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Despite these considerable advantages, randomized controlled trials are subject
to a number of limitations. In the first place, the costs associated with designing and
carrying out an RCT can be expensive, particularly when a large number of subjects is
required to achieve the desired power. Randomized controlled trials frequently contain
stringent inclusion and exclusion criteria speciying whom is allowed to participate. Thus,
the trial population may differ from the general population to a degree that the findings of
the trial may not be broadly applicable, which is to stay that the study lacks external
validitl. Finally, there are a number of circumstances where a randomized trial may be
impractical, unethical, or even impossible. For example, if a researcher is interested in
studying the effect of race on survival after diagnosis of a particular cancer, it would
obviously be impossible to randomize the race of the subjects. If one wanted to study the
effect of smoking on mortality, it would clearly be unethical to randomize subjects to
smoking or non-smoking.
Because of the limitations of RCTs, researchers are often forced to rely upon
studies that are observational in nature. In an observational study, the researcher has no
control over the treatment assignment for the subjects, instead they are "self-selected"
into the treatment and control groups2. Subjects in the treatment and control groups thus
may differ widely in terms of baseline covariates. A covariate that is correlated with both
the treatment and the outcome is known as a confounder. If subjects in the treatment
and control groups differ significantly on confounding variables, then subsequent
estimates of the treatment effect may be subject to considerable bias if steps are not
taken to control for the confounding factors.
Rubin gives an example of the effect confounding can have on estimates of
treatment effect, which I will summarize here 3 . Consider the case of a researcher
wishing to study the effects of smoking on mortality. He analyzes a cohort that consists
2

of frequent smokers and nonsmokers. Consider now that the non-smokers are, on
average, older than the smokers. If the researcher were to simply compare the mortality
rates of the smokers to those of the nonsmokers, he may very well find that the mortality
rate is higher in the nonsmokers. This observation does not account for the confounding
effect of age, in that older subjects are likely to have higher mortality rates regardless of
smoking status. If the researcher were to then re-analyze the data in a manner that
adjusts for the age difference between groups, he would then correctly observe that
smoking is indeed a risk factor for increased mortality.
If the number of confounding variables were relatively few, as in the example
above, it would be fairly straightforward to control for their effect and thus reduce the
bias observed in estimation of the treatment effect. One of the most common methods is
stratification, also referred to as subclassification by Cochran 4 . In brief, stratification
involves dividing the treatment and control groups into categories, or strata, based on
the levels of the confounding variable. In the example given by Rubin above, one may
divide the smokers and nonsmokers into categories based on age, such as younger,
middle-aged, and 0lder3 . The outcome variable can then be assessed within each strata,
and the results combined to get the overall estimated treatment effect. By performing
comparisons using 5 to 6 strata, Cochran has demonstrated that 90% or more of the
bias present in unadjusted analysis may be removed 4 .
Frequently, however, there are many potential confounders for which
investigators need to control. As the number of covariates increases, Cochran has
demonstrated that the number of strata grows in an exponential fasion. 5 For example, a
study with k dichotomous covariates would have 2k strata. Propensity score methods,
6

initially developed by Rosenbaum and Rubin in 1983, provide a convenient means for
addressing the problem of confounding by multiple covariates in observational studies
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and have become increasingly popular over the past two decades in the medical
literature.
Before specifying the derivation and use of the propensity score, it will first be
helpful to consider the conceptual framework upon which it operates, which is known as
the potential outcomes framework, or Rubin Causal Model?' 8. In this model, there are
two treatments (labeled 0 and 1) and an outcome of interest. For a sample of N subjects,
the ith subject has two potential outcomes, which are Y;(O) and Y;(1), which are the
outcomes when the ith subject receives treatment 0 and when the ith subject receives
treatment 1, respectively. In reality, each subject only receives one treatment, either the
active or the control.
Now let Z be an indicator variable for the treatment assignment, where Z=O for
the control treatment and Z=1 for the active treatment. The outcome observed for each
subject under the treatment received thus becomes:

The average treatment effect (ATE) thus becomes the difference between the
expectations between Yj(1) and Yj(O), that is to say:

ATE

= ~(1) -

~(O)

The average treatment effect is thus the effect of moving the entire population from the
untreated to the treated condition? In other words, the ATE is an estimate of the
difference in outcome if those who received one treatment instead received the other. In
the RCT setting, randomization allows for direct comparison of the treatment and control
groups. This can't be done in observational studies, however, because the subjects in
one treatment group differ systematically from those in the other treatment group. In
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order for direct comparisons to be meaningful in such a setting, a balancing score is
needed to even out the differences in covariates between the two treatment

groupS6.

A balancing score, b(x) (of which the propensity score is a single example), is a
function of the observed covariates x such that the conditional distribution of x given b(x)
is the same for both the treated (z=1) and control (z=O) groups. That is to say, x and z
are independent conditional on b(x). There are many balancing scores, the finest of
which is the vector of covariates itself,

x6 .

Having defined a balancing score, now we consider the distribution of the
treatment assignments, which is as follows:
e(x) = pr(z = llx)

and it is also assumed that

n
n

pr(zl, ... ,ZnIXl, ... ,xn )

=

e (xaZi{l- e(xaJ1-Zi

i=l

In the above equation, n is the number of subjects, while

Zi

is the indicator for treatment

assignment of patient i, and Xi is the vector of covariates for the ith subject.
The probability e(x) is known as the propensity score, and represents the
conditional probability of assignment to the treatment group, given the observed
covariates. If two subjects have the same propensity score, then the probability that
either of them would be assigned to the treatment group, conditional on the observed
covariates, is also equal. Thus it is as if a coin flip was performed to determine to which
treatment group the subject would actually be assigned. Herein lies the primary utility of
propensity score methods, in that they create what has been termed a "quasirandomized" experiment from observational data 9 .
5

An important assumption of the propensity score is that of strongly ignorable
treatment assignment6 , which states that treatment assignment and outcome are
conditionally independent given the vector of covariates, and that for each subject, there
is a possibility of assignment to either treatment group. In mathematical notation:
~(O), Yi(l) 1-

zlx, and 0 < pr(z

= llx) < 1

The first condition of strongly ignorable treatment assignment is also known as the "no
unmeasured confounders assumption,,7. Stated yet another way, the assumption is that
all variables that affect treatment assignment have been included in the propensity
score. The second condition of strongly ignorable treatment assignment

(0 < pr(z= 1Ix) < 1), may be stated alternatively that there must be sufficient overlap in
estimated propensity score between the treated and control groups. The region of
overlap is known as the zone of common supporf. At a given value of the propensity
score, the difference between the treatment and control means is an unbiased estimate
of the average treatment effect when treatment assignment is strongly ignorable.

In a randomized controlled trial, the propensity score is known, as the
assignment into treatment groups is controlled by the investigators. Remember that the
propensity score is simply the probability that a particular subject will be assigned to a
treatment group. In an RCT, treatment assignment is solely a function of the
randomization scheme, and thus propensity is known and subject to control by the
investigators. In most cases, the propensity score for each subject in an RCT would thus
be 0.5. In observational studies, on the other hand, the propensity score is unknown and
must be estimated using the measured covariates. Although several methods for
estimating the propensity score have been suggested 10-12 , by far the most commonly
used method is that of logistic regression 6 , 7,

6

In the logistic regression framework, the propensity score (p) is estimated as
follows:
P
log-l- = {J' x

-p

where {J' is the vector of regression coefficients and

x is the vector of measured

covariates, The major question in deriving the estimated propensity score then becomes
which covariates to include in the logistic regression model. Possible sets of covariates
include all measured baseline variables, all baseline covariates that affect the treatment
assignment, all covariates that affect the outcomes (potential confounders), and all
covariates that affect both the treatment assignment and the outcome (true
confounders( Although there is no universal agreement on which set is the best to
choose, there have been some studies to suggest that inclusion of only the potential or
true confounders leads to more precise estimation of the treatment effect13 , 14, Which
variables meet these requirements will often require subject matter expertise and/or
reference to the available literature, Austin has noted, however, that most baseline
characteristics are likely to affect both treatment assignment and outcome, so inclusion
of all measured baseline characteristics is generally safe?, There has been discussion in
the literature of using goodness of fit estimates such as the c-statistic to determine the
correct specification of the propensity score model, however such methods have been
shown to be ineffective in reducing confounding, and may actually result in a decreased
zone of common support between the treated and control groups 15, Thus, selection of
covariates to include in the propensity score model should be guided as stated above by
expert knowledge, reference to the literature, and empirical observation 15,16,
After the propensity score has been estimated, there are three common methods
for its use: matching on the propensity score, stratification on the propensity score, and
7

2
regression on the outcome of interest with the propensity score included as a covariate ,
6,7,9.

In general, matching has been demonstrated to result in greater balance between

the treated and untreated groups than the techniques of stratification and regression?' 13,
1? As matching (generally in a 1:1 fashion) is the most commonly employed method, and
is the method I will feature in the following chapters, the discussion here will be limited to
matching methodologies.
Having decided to match on propensity scores, the investigator is faced with a
number of choices as to how matching should actually be performed. The first choice is
whether to match with or without replacement2'? A potential drawback of matching with
replacement is that a single untreated subject may be matched with multiple treated
subjects. Another decision is whether to match using a simple nearest neighbor
algorithm (in which treated subjects are matched to untreated control with the closest
propensity score), or whether to impose a caliper on the maximum difference in
propensity score between the treated subject and untreated control for the match to be
considered valid.
If the zone of common support is limited, then simple nearest neighbor matching
will tend to result in poor matches being made for the treated subjects at the higher end
of the estimated propensity score distribution. In order to prevent this problem,
imposition of a caliper that specifies the maximum difference in propensity scores has
been proposed?' 18-20. There is no generally accepted caliper width, so the ultimate
judgment must be based on the degree of balance achieved between the matched
samples, as will be discussed later. Having specified an appropriate caliper, the
investigator must then choose between "greedy" matching and "optimal" matching.
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In a greedy matching scheme, once matches are made they are not broken?
Thus, once a control is matched to a treated subject, that control is removed from the
pool of potential controls for others in the treated group. An optimal matching strategy,
on the other hand, is formulated so that matches are made which minimize the total
distance in propensity scores between pairs. Comparison between the two schemes
have demonstrated that optimal matching performs no better than greedy matching in
producing balanced samples, which is the ultimate goal of propensity matching 21 . Luo
and colleagues present a nice graphical depiction of the choices facing the investigator
when implementing propensity score techniques 2 .
As stated above, the ultimate goal of propensity score matching is to create a
cohort of treated and control subjects that are balanced on relevant covariates. Checks
of the balance between the matched samples then becomes important to determine
whether the estimated propensity score and matching methodology have been
appropriately specified. In this area, there has been some controversy as to whether
significance testing is an appropriate method for determining balance on covariates in a
propensity matched sample.
On the one hand, Austin and others have argued against the appropriateness of
significance testing on the grounds that significance testing is confounded by sample
size?' 20, 22. In Austin's view, significance tests of balance may lack power to detect
important differences between covariates if the matched sample is small, while trivial
differences may be declared significant if the matched sample size is large?' 20. As an
alternative, Austin has suggested the standardized difference for continuous variables as
a more appropriate measure of balance. The formulation for the standardized difference
(d) is as fOllows 20 :

9

100 * Imeantreatment - meancontroll
d = ----;:======~=-
SEreatment

+ S~ontrol

2
Thus we see that the standardized difference places the difference in means between
the treatment and control in terms of the pooled variance of the two groups. There is no
widely agreed upon cutoff to define an acceptable standardized difference, though
Normand has defined a difference of less than 0.1 in absolute value to represent
appropriate balance has been achieved 23
On the other hand, Hansen has argued in favor of significance testing for the
assessment of covariate balance 24 . In Hansen's view, hypothesis tests for balance tend
to reject the null hypothesis of balance when the difference in covariates is enough to
introduce significant bias into the subsequent causal inferences. On the other hand,
significance tests of balance fail to reject the null hypothesis when differences between
covariates are small enough that any subsequent bias in the causal estimates is
ignorable. The use of significance testing for balance does have a tradition in the
literature 2 , 9, 25. Luo and colleagues make the reasonable suggestion that, if hypothesis
testing is to be used, then tests appropriate for matched pairs such as the paired t-test or
Mcnemar's test should be chosen2 .
Having estimated propensity scores, formed matched cohorts, and appropriately
assessed balance between the groups, the investigator is left with the final choice of how
to perform significance testing on outcomes. The basic distinction to be made is whether
the matched samples should be treated as independent. Schafer has argued that the
treated and control groups in the matched sample should be regarded as independenf'
16,

which would lead to tests such as the two sample t-test for continuous outcomes and
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Pearson's chi-squared test for categorical outcomes. Austin, on the other hand, has

made the argument that subjects matched on important baseline covariates are liKely to
have similar outcomes, and thus methods that account for the lack of independence
between groups are more appropriate. In this manner, Austin suggests methods such as
the paired t-test and Mcnemar's test for assessment of continuous and categorical
outcomes, respectivel/.
Having now described the basis of the propensity score and suggestions for its
use in observational studies, I will now turn to specific examples of how the propensity
score can be used in settings where randomized trials are either impossible or
impractical. In the first case, the disparity in donor organ quality between African
American and Caucasian recipients will be examined. This is a case where
randomization is clearly impossible, as recipient race is an intrinsic characteristic of the
patient not subject to investigator control. In the next case, outcomes after laparoscopic
versus open resection of hepatic colorectal metastases will be evaluated. A randomized
controlled trial in this setting is theoretically possible, but rendered infeasible given that
patients are unlikely to agree to be randomized to a more invasive procedure 26 .

11

CHAPTER II
THE IMPACT OF DONOR QUALITY ON THE OBSERVED DISPARITY IN GRAFT
SURVIVAL BETWEEN AFRICAN AMERICAN AND CAUCASIAN KIDNEY
TRANSPLANT RECIPIENTS
Kidney transplantation remains the gold standard for treatment of patients with
end stage renal disease when compared to long term maintenance dialysis, which has
been demonstrated across ethnic groups27. As the field of transplantation has matured a
number of disparities in access 28-30 to transplantation, as well as in post-transplant
outcomes 30-34 between African American and Caucasian recipients have come to light.
Several authors have proposed factors contributing to these disparities, including
socioeconomic31 , 34, 35, genetic36 , immunologic37 ,38, and even pharmacokinetic39 issues.

Issues of donor quality also playa major role in post-transplant outcomes.
Kidneys from African American donors, for example, have been shown to be associated
with an increased risk of graft loss32, 40, 41, especially when transplanted into other African
Americans 42 . The importance of donor quality in post-transplant outcomes is especially
clear when looking at kidneys from expanded criteria donors, which pose a 70% greater
risk of graft failure than lower risk organs 43 . Despite the known importance of donor
quality, there is a relative paucity of large scale studies examining racial disparities in
terms of donor quality in a systematic manner 44.
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We undertook this present study to determine the presence of and any possible
contributing factors to differences in donor quality between African American and
Caucasian first time recipients of deceased donor kidney transplants, as well as to
ascertain the effect of any donor quality disparity on post-transplant outcomes.
Patients and Methods
Selection of Patients for Analysis

After receiving an institutional review board exemption, an analysis of the United
Network for Organ Sharing/Organ Procurement and Transplantation Network database
as of 3/31/2011 was performed. The target population for this study was Caucasian or
African American first time recipients of deceased donor kidney alone transplants from
1/1/2000 through 12/31/2009.
Assessment of Donor Quality

The primary goal of this study was to determine disparity in donor quality
between African American and Caucasian recipients. The kidney donor risk index (DRI)
derived by Rao, et al.

45

was chosen as the measure for donor quality for this study as it

avoids the creation of arbitrary cutpoints in continuous data, and that it provides more
granular information than more traditional measures such as the expanded donor
criteria. The DRI includes donor age, race, history of hypertension and diabetes, serum
creatinine, cause of death, height and weight, donation after cardiac death status,
hepatitis C status, B and DR locus mismatch level, cold ischemic time, and whether an
en bloc or double kidney transplant is to be performed. The score represents the
estimated risk of graft failure relative to a hypothetical standard donor with a DRI of 1.0.
For example, a DRI of 1.3 confers a 30% greater risk of graft failure than the reference
donor.
13

Statistical Analysis
Comparisons were made between the African American and Caucasian recipient
cohorts. Continuous variables were summarized as mean/standard deviation and
analyzed using Student's t-test while categorical variables were summarized as
count/percentage and analyzed using the chi-squared or Fisher's exact test, where
appropriate. Graft survival was calculated as the time from transplant to graft failure, with
censoring at the time of death with a functioning graft or last follow-up (right-censoring)
in the case of Cox proportional hazards analysis

46

.

The cumulative incidence of graft

failure in African Americans versus Caucasians was calculated by competing risks
analysis 47 and compared using a modified chi-squared statistic as described by Gral

8

.

In this analysis, death and graft failure were treated as competing risks, while patients
still alive at the end of follow-up with a functioning graft were censored.
To control for confounders related to recipient race that may influence observed
differences in DRI, a 1: 1 propensity matched 49 cohort of African American and
Caucasian recipients was created using a nearest neighbor algorithm 50 . Propensity
scores were estimated through logistic regression, with immunologic (HLA-A, -B, andDR antigens, peak PRA, and ABO antigen), socioeconomic (payment source,
educational achievement, employment status, and UNOS Region), and medical (age,
recipient bmi, etiology of renal failure, recipient diabetes status, weight, gender, recipient
HCV status, recipient CMV status, and days on the waiting list) factors as independent
variables and recipient race as the dependent variable. The result of this model is to
assign each patient a propensity score that describes the probability of the patient either
being African American or Caucasian based upon the independent variables entered in
the model. The form of the model is as described above in Chapter I:

14

e(x) _
log 1 _ e(x) -

fJ

-1

x

Where e(x) is the propensity toward being African American, and x is the vector of
medical, immunologic, and socioeconomic baseline covariates described above. These
covariates were chosen on the empirical assumption that they are correlated with
recipient race and/or donor selection (which is the desired outcome to ultimately
analyze). Matching was on a 1: 1 nearest neighbor fashion based on the estimated
propensity score, with a caliper of 0.1 imposed to ensure that matching was within the
zone of common support. Furthermore, the matching algorithm was "greedy" in that once
made, matches were not broken. African American recipients without a corresponding
Caucasian control who had a propensity score within the specified caliper were
discarded.
After creation of the propensity matched cohort, balance on the covariates
included in the model estimating the propensity score was assessed using matched pair
techniques. Specifically, continuous covariates were compared using the paired t-test
and the Spearman signed rank test, where appropriate. Categorical covariates were
compared using McNemar's test or its extension for larger dimension square tables, or
conditional logistic regression for non-square tables. Differences in the overall DRI as
well as individual components were then assessed in the propensity matched cohort,
again using paired data techniques as described for assessment of balance.
To explore the contribution of DRI to disparities in graft survival between African
Americans and Caucasians, several Cox regression models were examined in
sequence. First univariable models were fitted with recipient race and DRI respectively
as the sole predictor variables to determine the baseline unadjusted hazard for graft
failure posed by these factors. Next, to control for other potentially relevant covariates, a
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multivariable Cox regression model was fitted using forward selection of variables
significant at the p<0.05Ievel. Factors considered in the model were the same
covariates used to create the propensity score described above. Donor risk index was
then included as a covariate in the third and final multivariable model. The difference
between the hazard ratios corresponding to African Americans was then examined in the
progressively adjusted models. Reductions in the hazard ratio would indicate that the
additional covariates partially explain the observed disparity in graft survival between
African American and Caucasian recipients.
As a final test of the contribution of DRI disparity to the difference in graft survival
between African Americans and Caucasians, graft survival was analyzed in a cohort of
African Americans and Caucasians matched on DRI. The matching process was similar
to that used in the propensity matching scheme, namely 1: 1 matching based on a
nearest neighbor algorithm. The hazard ratio for African American race in this matched
cohort was then compared to the unadjusted hazard ratio for African American race in
the overall cohort. The percent of excess hazard explained by matching on DRI was
calculated as (HRunmatched-HRmatched)/(HRunmatched-1 )*1 00%.51 The interaction between DRI
and recipient race was also examined by performing Cox proportional hazards
regression of graft survival stratified by DRI in the overall cohort. The three strata
analyzed were DRI <1, 1s;DRI<1.5, and DRI

~1.5.

Sensitivity analysis was also performed to determine whether significant bias
may have been introduced into the analysis by exclusion of patients with missing data
that did not allow for calculation of the DRI. First, chi squared analysis was performed to
determine whether patients with missing DRI data differed significantly by race. DRI for
the patients with missing component variables was then calculated using multiple
imputation, whereby five imputations were performed in which missing DRI component
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variables were predicted based on remaining DRI variables that were available for each
patients. The five imputations were then combined to give estimates of the mean and
standard deviation for the DRI in subset of patients with missing data. The imputed ORis
were then compared to the DRI for African Americans and Caucasians with complete
data to determine whether the patients with missing data were significantly different from
the subset with complete data. Cox proportional hazards analysis was then performed to
determine whether graft failure in the patients with missing DRI data was significantly
different from the patients who had complete data. All statistical analyses were
performed using SAS version 9.3 (SAS Institute, Cary, NC), with the exception of
competing risks analysis, which was performed in R (The R Project for Statistical
Computing).
Results
Overall Recipient and Donor Characteristics
There were 55,982 recipients included in the study with complete DRI data
collection, of whom 33,405 (59.67%) were Caucasian and 22,577(40.33%) were African
American. There were 3,916 Caucasians and 2,534 African Americans in the original
dataset that had missing data for DRI and thus were not included in the analysis. The
majority of patients analyzed were male (61.02%) at a mean age of 50.74 years at the
time of transplant. Mean time on the waiting list was 734.02 days. Peak PRA was a
mean of 12.79%. Remaining descriptive statistics of the recipients in this study are
detailed in Table 2.1.
The average age of donors was 38.14 years, with 59.70% being males
(n=33,423) and 7,496 (13.39%) African Americans. Terminal creatinine was a mean of
1.11 mg/dl. Cause of death was cerebrovascular accident in 21,717 (38.79%). Donation
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after cardiac death was uncommon (8.19% of all donors) as was utilization of HCV
positive donors (2.91%). Mean cold ischemic time was 18.59 hours. The mean DRI was
1.21. Remaining donor characteristics are summarized in Table 2.2.
Differences in Donor Risk Index By Recipient Race

African American recipients received kidneys from higher risk donors as
measured by most components of the donor risk index(table 2.1, 2.2). Specifically,
African Americans were more likely to receive a kidney from an African American donor
(20.37% vs. 8.67%; p<0.001). Utilization of hepatitis C positive donors was also
significantly higher among African American compared to Caucasian recipients (5.43%
vs. 1.20%; p<0.001). There was also a statistically significant, though likely not clinically
significant, increase in cold ischemic time for African American recipients (18.86 vs.
18.41 hours; p<0.001). Overall, donor risk index for African American Recipients was
significantly higher than for Caucasian recipients (1.27 vs. 1.17; p<0.001). The
distribution of the DRI in African American and Caucasian recipients is presented in
figure 2.1. There was no Significant difference in the percentage of African Americans
and Caucasians who received organs from extended criteria donors (17.66%, n=3986
vs. 17.98%, n=6005; p=0.330).
Propensity Matched Analysis

Matching on propensity score yielded a cohort of 2446 Caucasian and 2446
African American Recipients (distribution of propensity scores pre and post matching are
presented in Figure 2.2 and Figure 2.3, respectively). The African American and
Caucasian groups were well matched on etiology of renal failure (p=1.0), ABO type
(p=1.0), UNOS region (p=0.95), A 1 (p=0.99), A2 (p=0.92), B1 (p=0.76), B2 (p=1.0),
DR1 (p=0.81), and DR2 (p=0.99) haplotypes, payment source (p=1.0), HCV positivity
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(6.17% vs. 6.13%; p=0.95), cytomegalovirus positivity(7.15% vs. 7.85%; p=0.94), gender
(62.2% male vs. 63.0% male; p=0.55), educational achievement (p=0.91), diabetes
status (p=0.81), age (mean difference -0.61 years, 95% CI -1.32 -0.11; p=0.10), peak
PRA (mean difference - 0.20,95% CI -1.74 - 1.33; p=0.979), weight (mean difference0.58kg, 95% CI -1.69 - 0.52; p=0.30), body mass index (mean difference -0.32,95% CI 0.78 - 0.14; p=0.17), pretransplant creatinine (mean difference -0.08mg/dl, 95% CI -0.27
- 0.10; p=0.38), and days on the waiting list (mean difference -11.5 days, 95% CI -47.524.5; p=0.53).
In the propensity matched cohort, there remained a minor difference in mean DRI
between the African American (1.28) and Caucasian (1.25) cohorts (mean difference
0.03, 95% CI .005-0.06; p=0.02)(Figure 2.4). Comparison of donor risk index
components between the two groups are outlined in table 2.3. Notably, African
Americans are still significantly more likely than Caucasians to receive a kidney from an
African American donor (15.74% vs. 13.41%, OR 1.21,95% CI 1.03 - 1.41; p=0.02).
Furthermore, utilization of HCV positive donors remained significantly higher in African
American recipients (3.97% vs. 1.96%, OR 2.06, 95% CI 1.45-2.93; p<0.001).

Effect of Recipient Race and Donor Risk Index on Graft Survival
Both DRI and recipient ethnicity significantly correlated with graft survival in the
univariable models. The hazard ratio for each one point increase in DRI in the over the
baseline of 1.0 in the unadjusted model was 2.2 (95% CI 2.071-2.239; p<0.001). One,
five, and ten year cumulative incidence of graft failure for African Americans was 7.5%
(95% CI 7.2%-7.9%), 25.2% (95% CI 24.5%-25.9%), and 43.9% (95% CI42.4%-45.3%)
compared to 5.6% (95% CI 5.3%-5.8%), 14.8% (95% CI14.4%-15.3%), and 25.7%
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(95% CI 24.8%-26.6%) (p<0.001) for the Caucasian cohort. The hazard ratio for African
Americans relative to Caucasians in the unadjusted model was 1.8 (95% CI 1.7-1.9;
p<0.001). The median followup for the overall, African American, and Caucasian cohorts
was 37.2 months, 35.9 months, and 41.5 months, respectively. The number of graft
failures (not including death with a functioning graft) in the overall, African American, and
Caucasian cohorts were 10,132, 5,245, and 4,887, respectively.
The multivariable Cox regression model for graft survival after forward selection
included recipient race, age, and weight, etiology of renal failure, employment status,
UNOS region, payment source, and recipient hepatitis C status. The hazard ratio for
African Americans relative to Caucasians in this model was reduced to 1.5 (95% CI 1.31.6; p<0.001). After entering DRI as a covariate in the above multivariable model, the
hazard ratio for African Americans was further reduced to 1.3 (95% CI 1.2-1.4; p<0.001).
Hazard ratios for all other covariates included in the model are presented with the
supplementary material (Table 2.4).
As a further test of the importance of DRI disparities on the differential graft
survival seen with African American and Caucasian recipients, matching for donor risk
index yielded a cohort of 22,466 African Americans and 22,466 Caucasians with a mean
DRI of 1.26 for each group (p=1.0). The hazard ratio for African Americans relative to
Caucasians in this matched cohort was reduced to 1.6 (95% CI1.5-1.7; p<0.001), giving
a percent of excess hazard explained of 25%.
Finally, examination of the interaction between DRI and race in terms of graft
survival was undertaken using stratified analysis as outlined above. In the lowest DRI
stratum (DRI <1.0), the HR associated with African American Race was 2.1 (95% CI 1.92.2; p<0.001). In the middle stratum (1.0SDRI<1.5), the HR associated with African
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American race decreased to 1.6 (95% CI1.5-1.7; p<0.001). In the highest DRI stratum
(DRI~1.5),

the HR associated with African American race was further reduced to 1.4

(95% CI 1.3-1.5; p<0.001).
Sensitivity Analysis for Missing DRI Data
There were 2534 (10.09%) African Americans with missing DRI data compared
to 3916 (10.49%) Caucasians (p=0.106), indicating that patients with missing DRI were
equally distributed by race. Using multiple imputation as described above, the mean DRI
for African Americans with missing data was predicted to be 1.26 (0.465) compared to
1.27 (0.445) for those with complete data (p=0.486). The mean imputed DRI for
Caucasians with missing data was 1.15 (0.482) compared to 1.17 (0.542) for those with
complete data (p=0.058). Thus, the patients with missing data did not differ significantly
in terms of DRI from those with complete data. In terms of graft failure, Caucasians with
missing DRI had statistically similar risk of graft failure compared to those with complete
DRI (HR for missing DRI = 1.015, 95% CI 0.936-1.101; p=0.716). African Americans with
missing DRI data had significantly worse graft failure than their counterparts with
complete DRI data (HR for missing DRI = 1.114, 95% CI 1.033-1.200; p=0.005). Thus,
by not including the patients with missing data, our analysis of disparity in graft survival
between African Americans and Caucasians may actually be conservative.
Discussion
This study demonstrates that African American recipients receive significantly
"riskier" organs as defined by the DRI than their Caucasian counterparts, and that this
disparity cannot completely be explained by socioeconomic, immunologic, or other
medical factors. Furthermore, this disparity on organ donor quality has a significant
impact on graft survival. The negative effects of the donor quality disparity are illustrated
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by our analysis of graft survival, in which the percent of excess hazard explained by
matching on DRI was 25%. The analysis of graft survival between African Americans
and Caucasians indicates that the contribution of DRI to the observed higher risk of graft
failure in African Americans is most prominent in the higher DRI strata. Gaining a clear
understanding of the reasons underlying the lack of access to quality organs faced by
African Americans thus becomes crucial if outcomes are to be improved.
The propensity matched model of DRI demonstrates that multiple immunologic,
medical, and socioeconomic factors account for most, but not ali, of the disparity in DRI.
Two of the most important contributors to the disparity in organ quality appear to be
increased use of organs from African American and hepatitis C positive donors in African
American recipients. Although matching for HLA type and region did reduce the disparity
in usage of African American donor kidneys, the odds of an African American vs. a
Caucasian receiving a kidney from an African American donor remained 1.2 after
matching. That such a difference remains after extensive matching suggests the
influence of unmeasured factors which merit further study, such as the role of minor
blood group antigens. Other potential explanations include that African Americans
recipients and donors may live in closer proximity to each other, or perhaps that
transplant surgeons preferentially allocate organs to recipients of the same race.
The fact that African Americans remain more likely to receive a kidney from a
hepatitis C positive donor than their Caucasian counterparts after matching for recipient
hepatitis C status presents a similar quandary. Given that the patients were also
matched on educational achievement, it may be assumed that there existed a similar
level of sophistication on the part of recipients in both groups. Despite this, African
Americans apparently were more likely to receive a kidney from a hepatitis C positive
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donor than their Caucasian counterparts. This continued differential suggests an
opportunity for a more complete informed consent process.
The underlying causes for the disparity in kidney donor quality faced by African
Americans are likely multifactorial. Adjustment for socioeconomic, immunologic, and
clinical factors closes the gap somewhat, giving evidence to their significant role in the
disparity. Even when taking these factors into consideration, African Americans still
receive significantly more "risky" organs than their Caucasian counterparts. Given the
known barriers to transplantation faced by African Americans 30 , 52, transplantation with a
lower quality organ may be preferable to remaining on dialysis; however, such a decision
requires thoughtful and thorough informed consent and patient education. Furthermore,
the disparities in deceased donor organ quality faced by African American recipients
underscores the importance of efforts to increase living donation among the African
American community. Successful examples of such educational efforts can be seen in
the work of Callender and Foster 34,53.
If the disparity in post-transplant outcomes between African Americans and
Caucasians is to be remedied, then we clearly need to improve our efforts to understand
and address the donor quality gap. It is upon the transplant community to ensure that
the distribution of higher risk organs to African Americans as illustrated above is not the
result of a failure of transparency on our part. Patients place a tremendous amount of
trust in their physicians because of our "expert" status. We must ensure that such trust is
not misplaced by taking extraordinary efforts to ensure that patients are properly
educated to make the best decisions for themselves. Organ donor quality and its effect
on post-transplant outcomes should be a mandatory part the discussion held with the

patient when determining whether to accept a particular organ offer. Failure to clearly
outline the risks posed by donor factors would be to perpetuate the disparity in the
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quality of organs accepted by and for African American patients. As a prescriptive
measure, we echo Rao's call to include the DRI, or a similar measure of organ quality, in
both the allocation and consent processes 45 . In the end, the decision of whether or not to
accept a particular organ must lie with the patient, and be based on full disclosure of all
relevant information and informed consent. Only when we have fully disclosed and
discussed issues of organ quality with the patient can we say that informed consent has
truly taken place. That such an informed consent process can be effective is evidenced
by the fact that African Americans and Caucasians accepted organs from extended
criteria donors at similar rates in this study. Were potential recipients made as aware of
the risks of high DRI kidneys as they are of the risks of ECD kidneys, then perhaps the
gap in DRI between African Americans and Caucasians would be mitigated.
In this study we have outlined several factors that contribute to this gap in what
is, to our knowledge, the largest study to systematically address donor quality issues in
African American recipients. The disparities underscored by our study, such as use of
hepatitis positive and African American donors, certainly have more subtle effects on
graft survival than more traditional measures of donor quality such as the expanded
donor criteria, which were not significantly different in the matched cohort. When taken
all together, however, these small differences combine to produce a significant effect. It
is through acknowledging and paying appropriate attention to all the small details of
patient care that optimal outcomes are achieved. Furthermore, it may be preferable in
the future to preferentially allocate higher risk organs to patients with shorter life
expectancy in order to mitigate the effects of shorter expected graft longevity.
Despite this data, there remain other unmeasured factors yet to be determined
that merit future study. It will require further vigilance on the part of the transplant
community going forward to ensure that one of these factors is not the failure to disclose
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important issues of donor quality. Limitations of this study are largely a product of its
observational nature. We have included a number of potential confounders that can
potentially explain observed differences in DRI in our model; however, there may be
other factors which were not included and may contribute to residual confounding. The
most important of these is the inability to control for specific immunosuppression
protocols, which is the factor which likely has the greatest impact on graft survival, and
may have differing effectiveness across racial groups. Other factors may include minor
blood group antigens and willingness on the part of the patient(of either race) to accept
suboptimal organs as an alternative to remaining on dialysis
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.

We have also used

multivariable modeling of graft survival in order to control for the effects of confounders.
Though this approach has been widely used in the literature, there is the possibility that
such models do not completely remove the effects of confounding variables. Another
weakness of our Cox regression model is that the hazard associated with DRI and
African American race appear to change with time, thus making our estimates less
precise than a model where race and DRI were treated as time dependent. Though such
analysis would add precision to a model intended to predict survival, that was not the
goal of the current manuscript. The Cox regression analysis was of death censored graft
failure, which tends to overestimate risk in the setting of competing risks. Were death
instead treated as a competing risk, the observed difference in graft survival between
African American and Caucasians may differ from the findings in the current manuscript.
Another potential weakness is our use of the DRI as a surrogate for organ
quality, as it differs from traditional markers such as the expanded donor criteria. One
particular potential weakness of the DRI is that it does not completely isolate donor
factors, in that HLA mismatch is a product of both the donor and the recipient.
Nonetheless, we feel that DRI is the most appropriate proxy for donor quality for the
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reasons outlined previously in this manuscript. Finally, there were a number of patients
in the original dataset for whom complete information was not available to calculate the
DRI, and inclusion of these patients may potentially lead to somewhat different
outcomes. Although our sensitivity analysis indicates that the patients with missing
values were similar to those with complete data, the possibility of bias introduced by
exclusion of patients with missing data still remains.
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Table 2.1: Overall Recipient Characteristics

Variable
Male Gender
Hepatitis C Positive
Cytomegalovirus Positive
EnBloc Transplant
Double Kidney Transplant
Age (mean, std)
Peak Panel Reactive Antibody
(median, lOR)
A Locus Mismatch (median, IO~
B Locus Mismatch (median, IQR)
DR Locus Mismatch (median, IQR)
Total HLA Mismatch (median, lOR)
Height (cm, mean, std)
Days on the waitlist (median, lOR)

Caucasian
(n=33,405)
20582 (61.6%)
1022 (3.1%)
17373 (54.2%)
478i1.5%)
484(1.5%)
48.3 (14.1)
0(7)
1 (1)
1 (1)
1 (2)
4 (3)
170.2 (14.5)
478 (702)

African
American
(n=22,577)
13577 (60.1 %)
2178 (9.8%)
16079 (74.4%)
321 (1.4%)
374 (1.7%J
52.4 (15.0)

pvalue
<0.001
<0.001
<0.001
0.726
0.050
<0.001

0(14)
2 (1)
2 (1)
1 (1)
5 (1)
171.1 (13.6)
756 (973)

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

Table 2.1: Comparison of recipient characteristics between African Americans and
Caucasians. Categorical variables are presented as count(percentage). Abbreviations:
std(standard deviation), iqr(interquartile range), HLA(human leukocyte antigen).
Components of the DRI are highlighted in bold.
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Table 2.2: Donor Characteristics

African
Caucasian
Recipients
(n=33,405)

American
Recipients
(n=22,577)

pvalue
<0.001

Variable
Donor Risk Index
1.17iO.43)
1. 271 0 .451
Age (years, mean, std)
38.1 (17.2)
38.3 (16.81
0.186
Terminal Cr (mg/dl, mean,
std)
1.14 (0.97)
<0.001
1.0810.851
Weight (kg, mean, std)
77.4 (23.6)
77.7 (23.71
0.175
Height (em, mean, std)
169.3117.71
0.450
169.2117.71
Cold Ischemic Time (hours,
mean, std)
18.4 (8.9)
<0.001
18.919.51
Male Gender
19848 (59.4%1
0.092
13575160.1 %1
African American Race
289618.67%1
4600120.37%1 <0.001
History of Hypertension
8077 (24.18%)
5963 (26.41 %)
<0.001
History of Diabetes
1884 (5.64%)
1405 (6.22%)
0.004
Death From Stroke
12865 (38.51 %)
8952 (39.21 o/~
0.097
Donation after Cardiac Death 2631 (7.88%)
0.001
1954 18.65°/~
Hepatitis C Positive
402 (1.20o/~
<0.001
1226 15.43o/~
Table 2.2: Comparison of donor characteristics by recIpient race. Categorical
variablesare presented as count(percentage). Components of the Donor Risk Index are
highlighted in bold. Abbreviations: std(standard deviation).
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Table 2.3: Differences in Donor Risk Index Components in a Propensity Matched
Cohort of African American and Caucasian Recipients
Caucasian

African

P-

(n=2,446)

American

value

(n=2,446)

Donor Age (mean, std)

39.45(16.71 )

39.67(16.76)

0.64

Donor Weight(kg, mean, std)

79.00(24.42)

79.17(24.41 )

0.80

Donor Height (cm, mean, std)

169.4(17.7)

169.1(18.0)

0.61

Cold Ischemic Time (hours, mean,

19.12(10.99)

18.75(9.56)

0.21

B Locus Mismatch (median, iqr)

2 (1)

2 (1)

0.006

DR Locus Mismatch (median,iqr)

1 (1)

1 (1)

0.03

Donor Terminal Creatinine

1.16(0.83)

1.14(0.70)

0.45

African American Donor

328(13.41 %)

385(15.74%)

0.02

Diabetic Donor (n, %)

164(6.70%)

196(8.01%)

0.08

Hypertensive Donor (n, %)

704(28.78%)

706(28.86%)

0.95

CVA as cause of death (n, %)

984(40.23%)

974(39.82%)

0.77

Hepatitis C Positive Donor (n, %)

48(1.96%)

97(3.97%)

<0.001

std)

(mg/dl, mean, std)
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DeD Donor (n, %)

245(10.02%)

273(11.16%)

0.20

Double Kidney Transplant (n, %)

33(1.35%)

50(2.04%)

0.06

En Bloc Transplant (n, %)

33(1.35%)

35(1.43%)

0.81

Table 2.3 (cont). Abbreviations: DeD (donation after cardiac death), eVA
(cerebrovascular accident),std (standard deviation)
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Parameter

Parameter

P-

Estimate

value

HR

Lower
95%
CI

Upper
95%
CI

DRI

0.87

<0.001

2.38

2.23

2.54

African American Race

0.26

<0.001

1.30

1.21

1.40

AGE (years)

-0.02

<0.001

0.98

0.98

0.99

Weight (kg)

0.01

<0.001

1.01

1.01

1.01

0.14

0.04

1.15

1.01

1.32

-0.96

0.05

0.38

0.14

1.02

0.08

0.51

1.09

0.85

1.40

-0.01

0.98

0.99

0.41

2.38

1.19

0.24

3.28

0.46

23.33

-0.15

0.20

0.87

0.69

1.08

ANTI-GBM

0.36

0.47

1.44

0.54

3.84

FSGS

0.04

0.56

1.04

0.92

1.18

REFLUX NEPHROPA THY

-0.20

0.26

0.82

0.58

1.16

POL YC YS TIC KIDNEYS

-0.34

<0.001

0.71

0.62

0.82

NEPHRITIS

0.19

0.23

1.21

0.89

1.65

NEPHROPHTHISIS
DIABETES - TYPE I INSULIN
DEPENDENT IJUVENILE ONSET

0.80

0.17

2.22

0.71

6.91

0.18

0.81

1.19

0.29

4.90

-0.40

0.49

0.67

0.22

2.08

Etiology of Renal Failure
(Reference: Hypertensive
Nephrosclerosis)

OTHER
CRESCENTIC
GLOMERULONEPHRITIS
MEMBRANOUS
GLOMERULONEPHRITIS
MESANGIO-CAPILLARY 1
GLOMERULONEPHRITIS
MESANGIO-CAPILLARY 2
GLOMERULONEPHRITIS
IGA NEPHROPA THY

DIABETES - TYPE /I NON-
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INSULIN DEPENDENTIADUL T
ONSET
OXALA TE NEPHROPA THY

1.42

<0.001

4.13

2.06

8.31

CYSTINOSIS

-0.78

0.43

0.46

0.06

3.25

FABRY'S DISEASE

-0.94

0.35

0.39

0.06

2.76

AMYLOIDOSIS
SYSTEMIC LUPUS
ERYTHEMA TOSUS
PROGRESSIVE SYSTEMIC
SCLEROSIS
RENAL CELL CARCINOMA

-0.27

0.58

0.76

0.28

2.03

0.24

0.01

1.27

1.07

1.50

-0.34

0.73

0.71

0.10

5.05

-0.42

0.18

0.65

0.35

1.22

MYELOMA
HEMOL YTIC UREMIC
SYNDROME
HYPOPLASIAIDYSPLASIAIDYSG
ENSISIAGENESIS
CORTICAL NECROSIS

-0.26

0.79

0.77

0.11

5.47

0.31

0.30

1.37

0.75

2.48

-0.21

0.61

0.81

0.36

1.81

0.44

0.66

1.56

0.22

11.08

ACUTE TUBULAR NECROSIS

0.49

0.23

1.64

0.73

3.66

MEDULLARY CYSTIC DISEASE

0.59

0.12

1.81

0.86

3.81

SICKLE CELL ANEMIA
ACQUIRED OBSTRUCTIVE
NEPHROPA THY
ALPORT'S SYNDROME

-0.03

0.94

0.97

0.46

2.05

0.32

0.21

1.37

0.84

2.25

-0.70

0.01

0.50

0.29

0.86

FAMILIAL NEPHROPA THY

-0.40

0.49

0.67

0.22

2.08

GOODPASTURE'S SYNDROME

-0.15

0.66

0.86

0.45

1.67

0.03

0.76

1.03

0.85

1.24

0.15

0.84

1.16

0.29

4.64

-0.58

0.56

0.56

0.08

3.98

0.99

0.32

2.70

0.38

19.21

MALIGNANT HYPERTENSION
HENOCH-SCHOENLEIN
PURPURA
PRUNE BELL Y SYNDROME

DIABETES - TYPE I NONINSULIN DEPENDENT
IJUVENILE ONSET
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DIABETES - TYPE II INSULIN
DEPENDENT IADUL T ONSET

0.10

0.86

1.11

0.36

3.44

-0.20

0.03

0.82

0.68

0.98

0.24

0.33

1.27

0.79

2.05

-0.44

0.13

0.65

0.37

1.14

0.45

0.07

1.57

0.97

2.53

0.56

0.43

1.75

0.44

7.01

1.07

0.06

2.91

0.94

9.05

0.03

0.96

1.03

0.33

3.20

-0.11

0.55

0.90

0.63

1.28

0.16

0.75

1.17

0.44

3.14

RENAL ARTERY THROMBOSIS
CHRONIC NEPHROSCLEROSISUNSPECIFIED
CONGENITAL OBSTRUCTIVE
UROPATHY
SCLERODERMA

-0.83

0.41

0.44

0.06

3.11

-0.16

0.57

0.86

0.50

1.48

0.14

0.45

1.15

0.80

1.66

0.54

0.15

1.72

0.82

3.63

WEGENERS GRANULOMA TOSIS

-0.84

0.01

0.43

0.23

0.84

POLYARTERITIS

-0.69

0.49

0.50

0.07

3.58

SARCOIDOSIS

-0.26

0.61

0.77

0.29

2.06

LYMPHOMA

1.60

0.11

4.97

0.70

35.38

NEPHROLITHIASIS

0.20

0.45

1.23

0.72

2.08

-0.10

0.69

0.90

0.54

1.50

-0.51

0.61

0.60

0.09

4.29

0.54

0.13

1.71

0.85

3.44

-0.04

0.56

0.96

0.83

1.11

DIABETES MELLITUS - TYPE II

-0.02

0.69

0.98

0.90

1.08

DIABETES MELLITUS - TYPE

-0.31

0.15

0.73

0.48

1.12

CHRONIC
GLOMERULONEPHRITIS
UNSPECIFIED
MEMBRANOUS NEPHROPATHY
CHRONIC
GLOMERULOSCLEROSIS
UNSPECIFIED
ANALGESIC NEPHROPA THY
RADIA TlON NEPHRITIS
ANTIBIOTIC-INDUCED
NEPHRITIS
CANCER CHEMOTHERAPY
INDUCED NEPHRITIS
CALCINEURIN INHIBITOR
NEPHROTOXICITY
HEROIN NEPHROTOXICITY

DRUG RELA TED INTERSTITIAL
NEPHRITIS
CHOLESTEROL EMBOLIZA TlON
RAPID PROGRESSIVE
GLOMERULONEPHRITIS
DIABETES MELLITUS - TYPE I
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OTHER / UNKNOWN
Employment Status (reference:
Employed)
Unemployed

0.15

0.00

1.16

1.07

1.26

Unknown

0.08

0.19

1.08

0.96

1.21

Region 1

0.08

0.44

1.08

0.89

1.31

Region 2

0.09

0.12

1.09

0.98

1.22

Region 3

-0.19

0.00

0.83

0.74

0.93

Region 4

0.06

0.39

1.06

0.93

1.22

Region 5

-0.11

0.14

0.89

0.77

1.04

Region 6

-0.10

0.38

0.91

0.73

1.13

Region 7

-0.07

0.28

0.93

0.81

1.06

Region 8

-0.04

0.59

0.96

0.82

1.12

Region 9

0.05

0.46

1.05

0.92

1.21

-0.04

0.57

0.96

0.85

1.09

0.17

0.03

1.19

1.02

1.39

UNOS Region (reference: Region
11)

Region 10

Payment Source (reference:
Private Insurance)

Public insurance - Medicaid
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Public insurance - Medicare FFS
(Fee for Service)
Public insurance - Medicare &
Choice
Public insurance - Department of

0.13

0.00

1.14

1.05

1.24

0.15

0.00

1.16

1.06

1.28

0.18

0.31

1.20

0.85

1.69

0.03

0.85

1.03

0.73

1.47

-1.20

0.23

0.30

0.04

2.15

1.06

<0.001

2.88

1.74

4.79

Negative

-0.10

0.21

0.90

0.77

1.06

Not Determined

-0.03

0.73

0.97

0.80

1.17

VA
Public insurance - Other
government
Free Care

Public insurance - Medicare other
detail not specified

Hepatitis C Status (reference
unknown)

=

Positive
0.02
0.81
1.02
0.85
1.24
Table 2.4: Multlvanable Cox regression model of death censored graft failure Including
recipient race, donor risk index, and other potentially relevant covariates using a forward
selection model. Hazard ratios are presented relative to the reference class for
categorical covariates and for each one unit increase for continuous covariates.
Parameter estimates and corresponding 95% confidence intervals are given for factors
that reached statistical significance and thus were included in the final model. Factors
that did not reach significance and thus were not included in the model were as follows:
recipient body mass index, recipient creatinine, days on the waiting list, peak panel
reactive antibody, recipient ABO blood group, recipient HLA antigens (a locus, b locus,
and dr locus), recipient diabetes status, recipient cytomegalovirus status, recipient
gender, and recipient educational achievement.
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CHAPTER III
A PROPENSITY MATCHED ANALYSIS OF LAPAROSCOPIC VERSUS OPEN
RESECTION OF HEPATIC COLORECTAL METASTASES
Since the first reports of limited laparoscopic liver resection in the first half of the
1990s, the application of minimally invasive techniques to hepatic surgery has been
relatively slow55 . Acceptance of the technique within specialized centers has been
steadily gaining ground since Cherqui's initial report of 30 laparoscopic hepatectomies. A
recent review by Nguyen demonstrated 2,804 cases reported in the world literature 56 ,57.
Experienced centers are now performing the majority of liver resections in a minimally
invasive fashion, with several now reporting series of 300 patients or more58 , 59.
With respect to indication, laparoscopic resection for benign lesions gained
acceptance relatively early on 26 , 60. Enthusiasm for laparoscopic resection of malignant
lesions has been slower to develop, owing to concerns about the oncologic adequacy of
laparoscopic hepatectomy61. In the realm of colorectal cancer, laparoscopic resection of
the primary tumor has been demonstrated by randomized controlled trials to be
oncologically equivalent to open surgery, with the benefit of shorter postoperative length
of stay62. We have recently demonstrated the significant benefits of laparoscopic
hepatic lobectomy in comparison to open hepatic lobectomy with benefits of reduction in
adverse events, incision related adverse events, and reduction in hospital stay63. There
have now been a handful of retrospective reports demonstrating the equivalence of
laparoscopic and open hepatic resection for colorectal metastases as weIl 64-66 . This
study was undertaken to evaluate the safety and efficacy of
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laparoscopic resection of hepatic colorectal metastases as compared to a matched
group of patients undergoing open resection.
Patients and Methods

With IRS approval, a retrospective review of all patients undergoing laparoscopic
first resection of hepatic colorectal metastases by the division of surgical oncology at the
University of Louisville from 1995 to 2010 was undertaken. These patients were
compared to a cohort of patients undergoing open resection during the same period that
were matched on a 1: 1 basis. Matching was by propensity scoring 6 , with scores based
on patient age, size and number of lesions, performance of major hepatectomy or
synchronous colectomy, and Fong score 6?
Propensity scores were estimated by logistic regression, with the propensity
toward laparoscopic treatment [e(x)] being specified as follows:
e(x) _ -1
log 1 _ e(x) - {J x

Where

13-1 is the vector of regression

coefficients and x is the vector of covariates as

listed above.
After estimation of propensity scores, matched cohorts were created using
greedy nearest neighbor matching within a caliper of 0.1, as described in Chapter II. Two
propensity matched groups were constructed. In the "inclusive" cohort, controls
undergoing open resection were selected from the group of all patients undergoing open
resection from 1995 through 2010. A "restricted" cohort was also created in which the
controls undergoing open resection were selected from a group limited to those
undergoing open resection from 2004 (when the first laparoscopic resection was
performed) through 2010. The rationale for analyzing the inclusive and restricted cohorts
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separately is to limit both era bias and selection bias. Use of controls from the earlier
time period in the inclusive cohort has the limitation that there have been improvements
in patient care and adjuvant therapy over the past two decades. Thus, utilization of
controls undergoing open operation may introduce bias due to the improved adjuvant
therapy in the laparoscopic cohort, which represents a more recent group of patients. On
the other hand, using controls who underwent operation prior to the introduction of
laparoscopy minimizes selection bias, in that even the "easy" cases underwent open
resection prior to the introduction of laparoscopy. In the restricted cohort, the patients
undergoing open and laparoscopic resection are contemporaneous, thus minimizing
the effect of changes in adjuvant therapy. On the other hand, the restricted cohort is
subject to greater selection bias as the more difficult cases preferentially receive an
open operation.
Balance of the baseline covariates was assessed using the paired t-test for
continuous covariates and Mcnemar's test for categorical covariates. Further
comparisons were made between the matched groups in terms of patient demographics,
tumor characteristics, operative factors, short term outcomes, and overall (OS) and
disease free (DFS) survival. Resection margins were defined as either micsrocopically
positive (R1) or negative (RO). Baseline comorbidities were assessed using the Charlson
Comorbidity Index68 . Continuous variables were summarized as mean(standard
deviation) or median(interquartile range) and analyzed using the paired t-test or the
Spearman signed rank test, where appropriate. Categorical variables were summarized
as count(percentage) and compared using Mcnemar's test. Overall survival was
calculated from the time of resection to death or last followup according to Kaplan-Meier,
while disease free survival was the time from resection to recurrence, death, or last
followup. Differences in survival curves were compared using the log rank test or Cox
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proportional hazards regression. All statistical analyses were performed using SAS
version 9.3 (SAS Institute, Cary, NC), and p-values less than 0.05 were considered
significant.

Results
Analysis of the Inclusive Cohort
There were 35 patients in the laparoscopic cohort and 35 patients in the open
cohort. The groups were well matched on age, tumor size and number, body mass index
(8MI), Fong score, and Charlson Comorbidity Index68 (CCI) (Table 1.3). In terms of
operative procedure performed, 19(54.3%) of patients in the laparoscopic cohort
underwent major hepatectomy compared to 18(51.4%) in the open cohort
(p=0.808).Synchronous colectomy was undertaken in 3(8.6%) patients in the
laparoscopic cohort and 2(5.7%) patients in the open cohort (p=0.655).
Patients in the laparoscopic group had Significantly less operative blood loss
(202m I vs. 457ml; p=0.002) than those undergoing open resection. Transfusions were
required in 4 (15.4%) patients undergoing laparoscopic resection compared to 8 (30.8%;
p=0.206) in the open group. At least one postoperative complication was experienced
significantly less often by patients in the laparoscopic versus open group (22.9% vs.
48.6%; p=0.020). Among patients who did experience a complication, there was no
significant difference in the median grade of worst complication between the
laparoscopic and open groups (2.5 vs. 2.0; p=1.0). Length of stay was an average of 4.8
days versus 7.6 days in the laparoscopic versus open groups (p=0.001). Ninety day
mortality was 2.9% in both cohorts (p=1.0).
In terms of oncologic outcome, RO resection was achieved in 97.1 % (n=34) of
laparoscopically resected patients compared to 82.9% (n=29) of patients in the open
43

cohort (p=0.059). Overall survival at 1, 3, and 5 years in the laparoscopic and open
cohorts was 96.9%, 62.6%, and 35.8% versus 100.0%, 66.1 %, and 40.8% (Figure 3.1;
p=0.484). Disease free survival in the laparoscopic and open cohorts was 79.3%,
36.96%, and 15.4% versus 90.7%, 43.6%, and 26.2% at 1, 3, and 5 years (Figure 3.2;
p=0.117). There were no recurrences at laparoscopic port sites or at the laparotomy
incision.
Analysis of the Restricted Cohort

There were 35 patients undergoing laparoscopic resection and 35 matched
patients in the open cohort. The groups were well matched on age, tumor size and
number, body mass index (8MI), Charlson Comorbidity Index68 (CCI), and Fong score
(Table 3.1). Major hepatectomy was performed in 54.3% (n=19) of patients undergoing
laparoscopic resection compared to 42.9% (n=15; p=0.371) of patients undergoing open
resection. A synchronous colectomy was performed in 8.6% (n=3) of the laparoscopic
cohort and 8.6% (n=3; p=1.0) of the open cohort.
Average blood loss was statistically similar in the laparoscopic and open groups
(202ml vs. 327ml; p=0.213), as were rates of blood transfusion (15.4% vs. 34.6%;
p=0.096). At least one postoperative complication was experienced in a significantly
smaller percentage of the patients undergoing laparoscopic compared to open resection
(22.9% vs. 48.6%; p=0.039). Of the patients who did experience a complication, the
median grade of the worst complication was similar in the laparoscopic and open cohorts
(2.5 vs. 2.5; p=1.0). Length of stay was significantly shorter in the laparoscopic vs. open
cohort (4.8 days vs. 7.3 days; p=0.042).
In terms of oncologic outcomes, patients undergoing laparoscopic resection were
significantly more likely to have a margin negative resection than patients in the open
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cohort (97.1% vs. 80.0%; p=0.014).Overall survival at 1, 3, and 5 years in the
laparoscopic and open cohorts was 96.9%, 62.6%, and 35.8% vs. 91.4%, 63.0%, and
26.3% (Figure 3.3; p=0.535). Disease free survival at 1, 3, and 5 years in the
laparoscopic and open cohorts was 79.3%, 36.9%, and 15.4% vs. 79.3%, 45.0%, and
15.0% (Figure 3.4; p=0.637), respectively.

Discussion
Results with open resection of hepatic colorectal metastases have been
excellent, with several centers reporting 5 year survival in excess of 50%69.70. The group
at Memorial Sloan Kettering have reported ten year cancer specific survival to be 23%67
in a series of over 1,000 patients. Given these excellent results, the bar has been set
relatively high for the application of laparoscopic techniques to this disease. Specific
concerns about the oncologic adequacy of laparoscopy in general include port site
metastases, the trophic effect of pneumoperitoneum on malignant cells, and inability to
adequately inspect the peritoneal cavity, and lack of tactile sensation when inspecting
the liver61 . 71-75.

Experience has shown these fears to be largely unfounded; however. In
Nguyen's review of the world literature on laparoscopic liver resection, there were no
port site recurrences reported following laparoscopic resection of hepatic colorectal
metasases 76 . In the current study, there were no port-site recurrences. Randomized
trials of laparoscopic colon resection for cancer also failed to demonstrate increased
rates of wound recurrence with laparoscopy77. As such, fears over port site recurrence
appear to be unsupported by the available evidence.
Rates of margin negative resection in this series were also similar or better in the
laparoscopic versus open cohorts in this study, demonstrating that adequate delineation
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of intrahepatic tumor anatomy can be obtained during laparoscopic resection. It is worth
noting here the importance of facility with laparoscopic ultrasound as a key factor in
obtaining such results. The ability to perform intraoperative ultrasound has been noted
as one of the pre-requisite skill sets necessary before embarking on a program of
laparoscopic liver resection 26 . Finally, overall and disease free survival were equivalent
in the laparoscopic and open cohorts of this study. These results demonstrate that
laparoscopic resection for hepatic colorectal metastasis is oncologically equivalent to
open surgery.
In addition to oncologic equivalency, we have also demonstrated a number of
benefits to laparoscopic hepatectomy. Patients undergoing a minimally invasive
procedure experienced significantly less operative blood loss, and experienced
postoperative complications at less than half the rate of their counterparts in the open
cohort. Furthermore, length of stay was significantly shorter in the laparoscopic cohorts.
Another potential benefit of laparoscopic liver resection is for patients who present with
synchronous disease. Simultaneous resection of both the primary tumor and hepatic
metastases allows for less overall hospitalization by avoiding a second operation 78 , and
eliminates any delay in hepatectomy while patients receive adjuvant chemotherapy. The
ability to perform laparoscopic hepatectomy extends the benefits of minimally invasive
surgery to this patient population. These results confirm our prior study evaluating
laparoscopic hepatic lobectomy versus open hepatic lobectomy in which there were less
adverse events 63 .
Given the demonstrated patient benefits of laparoscopy across the field of
surgery, it is unlikely that a randomized controlled trial of laparoscopic versus open
hepatic resection will ever be undertaken. Thus, comparisons will be limited to
observational studies that are potentially confounded by selection bias. A strength of the
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current study is the utilization of propensity score based matching, which simulates
randomization in eliminating the confounding effects of variables used to create the
model. In utilizing this design, the treatment effect of laparoscopy versus open resection
in this study is more accurately estimated 49 . There remains the potential, however, that
residual confounding by unmeasured variables continues to exist. Another limitation of
this study is its relatively small sample size, with only 35 patients undergoing
laparoscopic resection. Despite these drawbacks, it appears that laparoscopic resection
is an effective and beneficial alternative to open resection for appropriately selected
patients with hepatic colorectal metastases. Further study will be needed as experience
increases to confirm these findings.
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Inclusive Cohort
Open
Lap
P-value
Age (years,
mean, std)
CCI
(median,
IQR)
8MI (kg/m Z,
mean, std)
Size of
Largest
Tumor (cm,
mean, std)
Number of
Lesions
(median,
IQR)
CEAattime
of Liver
Resection
(mean, std)
Node
Positive
Primary
Tumor (n,

%)
Fong Score
(median,
IQR)

Open

Restricted Cohort
Lap
P-value

0.629

62.7
(10.51

19.51

0.858

4111
28.1

0.526

5111

4111

0.128

16.0)

18.01

0.865

27.7
16.61

28.1
18.01

0.956

4.7
(3.2)

4.2
(3.1 )

0.474

3.712.51

4.2
13·11

0.438

111)

1111

0.162

1111

1111

0.648

45.2
(69.1)

52.0
(126.4)

0.790

71.6
(134.3)

52.0
(126.4)

0.152

21
(60.0%)

20(57.
1%)

0.808

23
(65.7%)

20
(57.1%)

0.467

1 (1)

~(2)

0.306

2 (1)

61.3
(9.6)

62.3
(9.5)

4 (1)
28.6

62.3

0.860
2J2)
Table 3.1: Baseline patient and tumor characteristics in the matched laparosopic and open
cohorts. The inclusive cohort includes patients from 1995 through 2010, while the restricted
cohort includes patients from 2002 through 2010. Continuous variables are presented as
mean(standard deviation) or median(interquartile range) where appropriate, and categorical
variables as count(percentage).
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Figure 3.1: Overall Survival (in months) in the matched open and laparoscopic groups of
the inclusive cohort.
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CHAPTER IV

CONCLUSIONS

Herein I have presented an overview of the utilization of propensity score
matching to reduce confounding in observational studies in the field of surgery. Although
the preeminent role of the randomized controlled trial for causal inference is
acknowledged, the field of surgery is unique in the limitations placed on conducting such
studies. On the one hand, the invasive nature of surgical procedures prevents proper
blinding, in that it would be unethical to perform a sham operation on patients in order to
have a control group. Another difficulty encountered is patient willingness to be
randomized. This is especially problematic in the evaluation of minimally invasive
procedures.
Often, minimally invasive procedures are developed prior to the conduct of any
formal study of their efficacy. The problem encountered is that after a number of centers
have established expertise in a particular minimally invasive procedure, patients will
seek out those surgeons specifically so that they can have the less invasive procedure.
Such patients are unlikely to consent to randomization that would potentially have them
undergo a more invasive operation. This is the case with laparoscopic liver resection 26 ,
which is why we are limited to observational studies such as the one presented in
Chapter III of
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this work. In other cases, the exposure to be studied is not modifiable by the
investigators, such as patient race in the analysis presented in Chapter II.
Given the limitations on the performance of randomized controlled trials in the
field of surgery, analysis based on the propensity score allows the investigator to create
a "quasi-randomized" study from observational data, with subsequently reduced bias in
estimation of the average treatment effect6 , 9. Propensity score analysis is not a cure all
for the problem of bias, however, and investigators and readers of such studies must
keep some caveats in mind.
The principle limitation of propensity score analysis is that of the strongly
ignorable treatment assignment assumption 6 , which Austin has also named the
requirement of "no unmeasured confounders"? A propensity matched cohort represents
selection of patients on observable covariates. Thus, any propensity analysis is subject
to bias introduced by potential confounders that were not measured. This is a particular
problem with retrospective studies such as those presented in Chapters II and III above.
For example, patients are now selected for laparoscopic or open liver resection based
on the surgeon's experience and perceived difficulty of the procedure. These two factors
are not distinctly quantifiable. Though the analysis in Chapter III was confined to a single
center, differences in surgeon experience are not likely to affect treatment selection.
Percieved difficulty of the operation, on the other hand, could not be measured directly
and thus controlled for. In this case, we are forced to use surrogates for difficulty, such
as tumor size and number, and requirement for a major hepatectomy in the case of the
analysis in Chapter III. It remains likely though, that these surrogates did not completely
capture the perceived difficulty of the operation, thus leaving the potential for residual
bias in the study.
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Another requirement of the strong ignorability assumption is that there must be
enough overlap in propensity scores between the treated and control groups. As noted
in Chapter I, a simple nearest neighbor matching algorithm may lead to poor matches for
treated subjects in the upper tail of the propensity score distribution. Imposition of an
appropriate caliper on the maximum difference in propensity scores for a match to be
valid has thus become a popular and important method of ensuring that the matched
samples are limited to the region of common support7 , 18, 20.
Finally, a propensity score matching scheme is only as good as the balance
attained between the treated and control groups on measured covariates. Thus,
ensuring proper assessment of balance is critical. Although the most appropriate method
for evaluating balance remains a controversial subject, it is critical for investigators to
explicitly state the methodology used and results of such analysis in order for readers to
properly evaluate the study. Currently, it appears that either the method of standardized
difference suggested by Austin 20 or the use of hypothesis tests for paired data 2 ,24 are
both acceptable. With the above mentioned caveats, propensity matching is a valuable
tool for creating nearly unbiased estimates of the treatment effect in cases where proper
randomized studies are either infeasible or impossible.
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